KY SBIR/STTR Matching Grant

New Jersey Re-assigning In State Employees (NJ RISE) is a new program to incentivize businesses to re-assign New Jersey residents who are working in another state to a New Jersey location. The $10 million NJ RISE Program will provide grants to companies to relocate its New Jersey-resident employees, ensuring a residents’ income taxes stay in New Jersey, which will help increase tax revenue. NJ RISE’s goal is to increase New Jersey’s Gross Income Tax Withholdings by encouraging eligible businesses to re-assign their out of state New Jersey resident employees to New Jersey by issuing an incentive based upon on the employee’s withholdings. The NJ RISE Program is a pilot program that will provide grants to businesses principally located out of state that re-assign New Jersey residents currently assigned to work in a state that employs the “convenience of employer” income taxation rule to work in a New Jersey location. The grant is equal to the amount of New Jersey Gross Income Tax withholdings of the re-assigned resident employees during one tax year of the business, not to exceed $500,000 in the aggregate per business. The sum of all grants approved will not exceed $10 million per State fiscal year. States such as Delaware, Nebraska, and New York use “convenience of employer” where an employee who resides out of state is taxed based on the employer’s assigned location. For example, if a New Jersey-resident works in a state with “convenience of employer” (State A) three days a week and from home the other two days, the employee will be taxed by State A for all five days, because the work done from home in New Jersey was at the convenience of the employer.

The Dunn County Small Business Development Grant Program will offer eligible businesses up to $10,000 of funding to continue growing their operations and become more efficient. The grant funding can be used to access technical assistance through organizations like Western Dairyland Economic Opportunity Council and the Center for Innovation and Development at the University of Wisconsin Stout, help startups cover the cost of commercial space, and to match funding granted through other Economic Development Loan Fund Programs like the Revolving Loan Fund or Regional Business Fund.

If your business is in the home services industry, you may be eligible for a $10,000 grant from Jobber We want to recognize your accomplishments and accelerate your plans for the future, and have 15 grants worth $10,000 each to award to every type of home service professional. Any blue collar business owner or aspiring business owner aged 18 is eligible to apply.

The NICHD Small Research Grant Program (R03Basic Experimental Studies with HumansRequired) supports clinical trials that fall within the NICHD mission and also meet the criteria for basic science experimental studies involving humans (BESH), referred to in NOT-OD-18-212 as prospective basic science studies involving human participants. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind.

This Notice of Funding Opportunity (NOFO) invites applications that propose to use mouse models to conduct rigorous preclinical testing of drugs or drug combinations currently used for other conditions, as well as investigational drugs at various stages of clinical development, predicted to be efficacious in AD/ADRD. This initiative will also support preclinical testing of repurposable or investigational drug candidates in combination with non-pharmacologic interventions leading to robust translational outcomes. The central goal is to establish robust proof of concept that will enable rational drug repurposing and combination therapy development for the treatment and prevention of AD/ADRD.